Teriflunomide-A-77-1726-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemETeriflunomideCat. No.: HY-15405CAS No.: 163451-81-8Synonyms: A 77-1726分式: CHFNO分量: 270.21作靶點(diǎn): Others作通路: Others儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 26 mg/mL (96.22 mM; Need ultra

2、sonic and warming)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 3.7008 mL 18.5041 mL 37.0083 mL5 mM 0.7402 mL 3.7008 mL 7.4017 mL10 mM 0.3701 mL 1.8504 mL 3.7008 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Teriflunomide來氟特的活性代謝產(chǎn)物， 于治療類風(fēng)濕性關(guān)節(jié)炎的藥物。 它抑制嘧啶合成，因此有效降低T細(xì)胞和B細(xì)胞增殖。

3、體外研究Teriflunomide primarily acts as an inhibitor of dihydroorotate dehydrogenase (DHODH), a key mitochondrialenzyme involved in the de novo synthesis of pyrimidines in rapidly proliferating cells. By reducing the activityof high-avidity proliferating T lymphocytes and B lymphocytes, teriflunomide li

4、kely attenuates the1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEinflammatory response to autoantigens in MS. Thus, teriflunomide can be considered a cytostatic rather thana cytotoxic drug to leukocytes 1.體內(nèi)研究 Teriflunomide has demonstrated beneficial effects in two independent animal models of d

5、emyelinatingdisease. In the dark agouti rat model of experimental autoimmune encephalitis (EAE), teriflunomideadministration results in clinical, histopathological, and electrophysiological evidence of efficacy both as aprophylactic and therapeutic agent. Similarly, in the female Lewis rat model of

6、EAE, teriflunomideadministration results in beneficial prophylactic and therapeutic clinical effects, with a delay in disease onsetand symptom severity 1.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Expert Rev Clin Immunol. 2019 Jul;15(7):801-808. Biomed Pharmacother. 2019 Aug.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Oh J, et al. An update of teriflunomide for treatment of multiple sclerosis. Ther Clin Risk Manag. 2013;9:177-90.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.